Lindbrook Capital’s Cellectis CLLS Stock Holding History

Lindbrook Capital’s Portfolio CLLS Stock Details CLLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,529	Closed	-$12K	–	2487
2021 Q4	$12K	Buy	1,529 +1,066	+230%	+$10.5K	﹤0.01%	1195
2021 Q3	$6K	Buy	463 +293	+172%	+$4.06K	﹤0.01%	1169
2021 Q2	$3K	Sell	170 -62	-27%	-$1.04K	﹤0.01%	1449
2021 Q1	$5K	Hold	232	–	–	﹤0.01%	1244
2020 Q4	$6K	Hold	232	–	–	﹤0.01%	1101
2020 Q3	$4K	Sell	232 -124	-35%	-$2.2K	﹤0.01%	1161
2020 Q2	$6K	Buy	356 +247	+227%	+$3.76K	﹤0.01%	999
2020 Q1	$1K	Sell	109 -1,899	-95%	-$28.3K	﹤0.01%	1417
2019 Q4	$34K	Buy	2,008 +1,249	+165%	+$16.7K	0.01%	556
2019 Q3	$8K	Buy	759 +389	+105%	+$5.23K	﹤0.01%	946
2019 Q2	$5K	Buy	+370	New	+$6.61K	﹤0.01%	1050
2019 Q1	–	Sell	-168	Closed	-$2K	–	1405
2018 Q4	$2K	Buy	+168	New	+$3.9K	﹤0.01%	1162

Other funds holding CLLS

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Bpifrance Maisons Alfort, Cedex, France $1.65B AUM 19.85% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Lindbrook Capital's CLLS Position: Q1 2022 in Review

Lindbrook Capital sold out of Cellectis (CLLS) in Q1 2022, closing a stake of 1,529 shares — an estimated $12K sold.

Lindbrook Capital first reported a position in CLLS in Q4 2018 and held it in 12 quarters. The position peaked at $34K in Q4 2019. 51 funds tracked by Wall St. Rank hold CLLS as of Q1 2022.

Lindbrook Capital reported no remaining Cellectis position as of Q1 2022 after selling out during the quarter.
Lindbrook Capital sold 1,529 Cellectis shares in Q1 2022, an estimated $12K.
Lindbrook Capital first reported a position in Cellectis in Q4 2018 and held it in 12 quarters.
Lindbrook Capital's Cellectis position peaked at $34K in Q4 2019.
51 funds tracked by Wall St. Rank held Cellectis as of Q1 2022.

Based on Lindbrook Capital's 13F filing for Q1 2022, filed 21 Apr 2022.